Table 1. Baseline characteristics of... | American Society of Hematology

Table 1.

Baseline characteristics of included studies

Trial name	Authors (trial identifier)	Phase	Regimen	No.	Median age (range), y	DH/TH lymphoma, %	Stage III/IV, %	Median no. of previous therapy (range)	Prior ASCT, %	Refractory to last prior treatment, %
Bispecific antibody
EPCORE NHL-1	Thieblemont et al¹⁵ (NCT03625037)	2	Epcoritamab	157	64 (20-83)	0.131	0.752	3 (2-11)	0.197	0.828
NR	Dickinson et al¹⁴ (NCT03075696)	2	Glofitamab	154	66 (21-90)	0.129	0.753	3 (2-7)	0.182	0.857
NR	Bartlett et al¹⁸ (NCT02500407)	2	Mosunetuzumab	88	66.5 (24-96)	0.193	0.841	3 (2-13)	0.17	0.795
ELM-2	Poon et al¹⁷ (NCT03888105)	2	Odronextamab	140	66 (24-88)	0.193	0.80	2 (2-8)	0.157	0.864
NR	Song et al²⁰ (NCT04657302)	2	Glofitamab	30	57.5 (20-82)	NR	0.90	2 (2-6)	0.10	0.90
EPCORE NHL-3	Izutsu et al²¹ (NCT04542824)	2	Epcoritamab	36	68.5 (44-89)	0.0	0.778	3 (2-8)	0.194	0.806
CAR T cell
NR	Schuster et al¹¹ (NCT02030834)	2	Tisa-cel	14	58 (25-77)	0.214	0.643	3 (1-8)	0.5	0.86
ZUMA-1	Neelapu et al¹⁰ (NCT02348216)	2	Axi-cel	111	58 (51-64 [IQR])	0.095	0.775	3 (2-4)	0.189	0.604
JULIET	Schuster et al¹² (NCT02445248)	2	Tisa-cel	115	56 (46-84)	0.27	0.765	3 (2-6)	0.487	0.548
TRANSCEND NHL 001	Abramson et al¹³ (NCT02631044)	Seamless	Liso-cel	269	63 (54-70)	0.134	NR	3 (2-4)	0.335	0.673
RELIANCE	Ying et al¹⁹ (NCT04089215)	2	Relmacabtagene	59	56 (18-75)	0.051	NR	2 (2-7)	0.102	0.814
NR	Kato et al²⁰ (JapicCTI-183914)	2	Axi-cel	16	58 (44-70)	0.067	0.5	3 (NR)	0.375	0.625
NR	Park et al²¹ (NCT04148430)	2	Axi-cel/tisa-cel	27	62 (25-77)	NR	0.61	3 (2-5)	0.19	0.71
NR	Jacobson et al²⁶ (NCT03954106)	2	Axi-cel	25	68 (31-78)	NR	NR	2 (1-6)	0.20	0.84
NR	Strati et al²⁷ (NCT04432506)	1	Axi-cel	20	58 (26-81)	NR	0.95	3 (2-8)	0.05	1.00
OUTREACH	Godwin et al²⁵ (NCT03744676)	2	Liso-cel	82	66 (28-86)	0.18	NR	2 (2-6)	0.16	0.91

Trial name	Authors (trial identifier)	Phase	Regimen	No.	Median age (range), y	DH/TH lymphoma, %	Stage III/IV, %	Median no. of previous therapy (range)	Prior ASCT, %	Refractory to last prior treatment, %
Bispecific antibody
EPCORE NHL-1	Thieblemont et al¹⁵ (NCT03625037)	2	Epcoritamab	157	64 (20-83)	0.131	0.752	3 (2-11)	0.197	0.828
NR	Dickinson et al¹⁴ (NCT03075696)	2	Glofitamab	154	66 (21-90)	0.129	0.753	3 (2-7)	0.182	0.857
NR	Bartlett et al¹⁸ (NCT02500407)	2	Mosunetuzumab	88	66.5 (24-96)	0.193	0.841	3 (2-13)	0.17	0.795
ELM-2	Poon et al¹⁷ (NCT03888105)	2	Odronextamab	140	66 (24-88)	0.193	0.80	2 (2-8)	0.157	0.864
NR	Song et al²⁰ (NCT04657302)	2	Glofitamab	30	57.5 (20-82)	NR	0.90	2 (2-6)	0.10	0.90
EPCORE NHL-3	Izutsu et al²¹ (NCT04542824)	2	Epcoritamab	36	68.5 (44-89)	0.0	0.778	3 (2-8)	0.194	0.806
CAR T cell
NR	Schuster et al¹¹ (NCT02030834)	2	Tisa-cel	14	58 (25-77)	0.214	0.643	3 (1-8)	0.5	0.86
ZUMA-1	Neelapu et al¹⁰ (NCT02348216)	2	Axi-cel	111	58 (51-64 [IQR])	0.095	0.775	3 (2-4)	0.189	0.604
JULIET	Schuster et al¹² (NCT02445248)	2	Tisa-cel	115	56 (46-84)	0.27	0.765	3 (2-6)	0.487	0.548
TRANSCEND NHL 001	Abramson et al¹³ (NCT02631044)	Seamless	Liso-cel	269	63 (54-70)	0.134	NR	3 (2-4)	0.335	0.673
RELIANCE	Ying et al¹⁹ (NCT04089215)	2	Relmacabtagene	59	56 (18-75)	0.051	NR	2 (2-7)	0.102	0.814
NR	Kato et al²⁰ (JapicCTI-183914)	2	Axi-cel	16	58 (44-70)	0.067	0.5	3 (NR)	0.375	0.625
NR	Park et al²¹ (NCT04148430)	2	Axi-cel/tisa-cel	27	62 (25-77)	NR	0.61	3 (2-5)	0.19	0.71
NR	Jacobson et al²⁶ (NCT03954106)	2	Axi-cel	25	68 (31-78)	NR	NR	2 (1-6)	0.20	0.84
NR	Strati et al²⁷ (NCT04432506)	1	Axi-cel	20	58 (26-81)	NR	0.95	3 (2-8)	0.05	1.00
OUTREACH	Godwin et al²⁵ (NCT03744676)	2	Liso-cel	82	66 (28-86)	0.18	NR	2 (2-6)	0.16	0.91

DH, double-hit; IQR, interquartile range; TH, triple-hit.